Alnylam Pharmaceuticals Inc
$ 310.94
0.41%
20 Apr - close price
- Market Cap 41,317,286,000 USD
- Current Price $ 310.94
- High / Low $ 312.25 / 305.00
- Stock P/E 133.47
- Book Value 5.96
- EPS 2.32
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.73 %
- 52 Week High 495.55
- 52 Week Low 231.76
About
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$449.12
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-10-30 | 2025-07-31 | 2025-05-01 | 2025-02-13 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 1.25 | 2.9 | -0.51 | -0.01 | 0.06 | -0.5 | -0.13 | -0.52 | -1.1 | 1.15 | -2.21 | -1.4 |
| Estimated EPS | 1.24 | 1.44 | -0.7 | -0.37 | -0.14 | -0.39 | -1.08 | -1.18 | -1.32 | -1.34 | -1.37 | -1.77 |
| Surprise | 0.01 | 1.46 | 0.19 | 0.36 | 0.2 | -0.11 | 0.95 | 0.66 | 0.22 | 2.49 | -0.84 | 0.37 |
| Surprise Percentage | 0.8065% | 101.3889% | 27.1429% | 97.2973% | 142.8571% | -28.2051% | 87.963% | 55.9322% | 16.6667% | 185.8209% | -61.3139% | 20.904% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.92 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALNY
2026-04-20 02:39:52
Alnylam Pharmaceuticals, Inc. has seen its stock valuation revised due to current market dynamics, with its stock priced at $322.11, following a 42.35% year-over-year return but a 19.00% year-to-date decline. Technical indicators predominantly suggest a bearish outlook, despite the company's significant long-term resilience with a 365.81% return over the past decade. The stock's performance outpaced the S&P 500 over the past year and decade, but has underperformed year-to-date.
2026-04-19 14:39:12
Alnylam Pharmaceuticals (NASDAQ:ALNY) has seen a revised stock evaluation due to changing market conditions, with its stock currently priced at $320.13. Despite a year-to-date decline of 19.49%, the company has demonstrated strong long-term performance, outperforming the S&P 500 over one, five, and ten-year periods. Technical indicators suggest a mildly bearish outlook, highlighting a cautious market environment for the pharmaceutical company.
2026-04-18 13:10:11
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has been identified as a top "Growth at a Reasonable Price" (GARP) stock pick due to its strong growth fundamentals and acceptable valuation within the biotechnology industry. The company boasts significant past and projected EPS and revenue growth, alongside solid profitability and financial strength metrics. While it carries some debt, its healthy free cash flow and low Altman-Z score suggest stability, making it an attractive candidate for investors seeking growth without excessive pricing.
2026-04-18 09:08:48
GF Fund Management CO. LTD. significantly increased its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 989.1% in Q4, acquiring an additional 27,665 shares to hold a total of 30,462 shares valued at approximately $12.11 million. Despite this institutional interest, company insiders have been net sellers, offloading 38,656 shares worth $12.37 million in the past 90 days. Alnylam Pharmaceuticals missed its Q4 EPS and revenue estimates, though analysts maintain a "Moderate Buy" rating with a consensus price target of $472.78.
2026-04-17 16:40:01
JP Morgan has reaffirmed its Overweight recommendation for Alnylam Pharmaceuticals (ALNY). The investment bank continues to monitor the company's performance, but no further details were provided in the excerpt.
2026-04-17 06:40:01
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced it will report its first-quarter 2026 financial results on Thursday, April 30, 2026, before market open. The company will host a conference call and webcast at 8:30 am ET on the same day to discuss the results and future expectations. A live audio webcast will be available on the Investors section of Alnylam's website, with an archived version available approximately two hours after the event.
